Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company…

Xenon stock lost 30%, but the FDA story is more complicated

Xenon Pharmaceuticals (XENE) provided investors with two very different updates on the same drug, and Wall Street paid attention to the troubling one. Shares of the Vancouver-based biotech company plummeted as much as 30% on Sept. 18 after Xenon temporarily halted recruitment of additional…

Xenon Pharmaceuticals (XENE) Could Be 47% Undervalued Following Psychiatry Trial Pause

Xenon Pharmaceuticals (XENE) is in focus after a sharp selloff tied to safety concerns in high profile psychiatry trials, just as its New Drug Application for azetukalner in focal seizures advanced with the FDA. The sharp one-day share price drop of about 31% and roughly 35% decline over 30 days suggest risk perceptions around Xenon Pharmaceuticals have reset quickly after the psychiatry enrollment pause, even though the NDA news keeps attention…